GBM66 GBM Model

GBM66, a Patient-Derived Xenograft (PDX) model, offers a unique perspective on brain cancer. Utilize this model to unravel disease mechanisms and discover innovative treatment options. PDX models like GBM66 play a pivotal role in preclinical drug discovery, enabling researchers to assess potential drug candidates in a controlled environment. GBM66 closely replicates the patient’s tumor, offering valuable insights into treatment efficacy and safety. By using GBM66, you can accelerate the development of targeted therapies for brain cancer, benefiting patients worldwide.

Model Details

Cancer Location: Intracranial
Cancer Type: Brain Cancer
Model Name: GBM66
Mouse Strain: Nu/Nu
WES: Yes
Methylation: Yes
Patient Treatment History: Yes

GBM66 Survival

Survival of orthotopic intracranial implanted  GBM66 in Nu/Nu mice  (n=11)

Request Additional GBM Model Data

Contact Us

Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our
expert staff today to get started.

Skip to content